DEVELOPMENTS IN INFERIOR VENA-CAVA FILTERS - A EUROPEAN VIEWPOINT
DEVELOPMENTS IN INFERIOR VENA-CAVA FILTERS - A EUROPEAN VIEWPOINT
复制标题
DOI：
10.1055/s-2008-1074774
复制
发表时间：
1994-12-01
影响因子：
1.4
通讯作者：
GUNTHER, RW
中科院分区：
文献类型：
--
作者：
NEUERBURG, J;GUNTHER, RW
尽管抗凝剂和其他预防措施的使用大大减少了术后血栓栓塞事件，但肺栓塞仍然是一种风险。人们尝试了许多预防复发性肺栓塞的方法：Homans于1934年首次提出永久性结扎下腔静脉（IVC）。1从那时起，直到20世纪80年代末，手术进行了部分或完全的腔静脉阻断。迄今为止，经皮入路是首选，IVC滤器已逐渐取代IVC结扎或折叠术。为此，已获得批准的或研究用腔静脉滤器的数量不断增加。然而，目前还没有最佳的设备。2'3本文的目的是深入了解腔静脉滤过装置的种类，主要重点是目前在欧洲临床使用但尚未获得美国食品药品监督管理局（FDA）批准的装置。
Although the use of anticoagulants and other prophylactic measures has substantially reduced postoperative thromboembolic events, pulmonary embolism remains a risk. Many approaches for the prevention of recurrent pulmonary embolism have been tried: permanent ligation of the inferior vena cava (IVC) was first suggested by Homans in 1934.1 From that time on until the late 1980s partial or complete caval interruption was performed sur-gically. To date, the percutaneous access is preferred, and filters for the IVC have gradually replaced IVC ligation or plication. For this purpose a continuously increasing number of approved or investigational caval filters have been made available. However, the optimal device is not yet available. 2'3 It is the aim of this article to give insight into the variety of caval filtration devices, with the primary emphasis being on those devices that are currently in clinical use within Europe but not yet approved by the Food and Drug Administration (FDA) in the United States.